Data in Biotech

In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine.

What you'll learn in this episode:

>> How 3D printing is enabling customized bone scaffolds and regenerative therapies

>> The role of AI in optimizing pharmaceutical 3D printing parameters

>> How organoids can act as micro-organs for testing and computation

>> The promise and challenge of personalized, on-demand drug manufacturing

>> Why collaboration between data scientists and biopharma researchers is critical

Meet our guest

LR Jaidev Chakka is a Principal Scientist at the University of Mississippi School of Pharmacy, pioneering 3D bioprinting, drug delivery, and organoid research to revolutionize patient care and pharma manufacturing.

About the host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Jaidev Chakka on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions.

What you'll learn in this episode:

>> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients

>> The benefits and challenges of working with peptides and GLP-1 receptor agonists

>> How the SCIEX 8600 enhances detection of low-concentration analytes

Meet our guests

Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development.

Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making.

About the host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Isa Kupke on LinkedIn 
• Connect with Callie Celichowski on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science.

What you'll learn in this episode:

>> Why traditional mass spectrometry falls short in modern bioanalysis

>> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs

>> The role of high-resolution systems in detecting complex drug metabolites

>> How automation tools are streamlining workflows for bioanalytical scientists

>> The complementary role of AI and ML in mass spec data analysis

Meet our guest

Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech. 

About the host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Eshani Galermo on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development.

What you'll learn in this episode:

>> How amorphous solid dispersions improve solubility and stability in drug products

>> Why formulation decisions hinge on early data collection and modeling

>> The role of data infrastructure in formulation R&D and knowledge transfer

>> How Serán BioScience collaborates closely with clients to solve complex drug development challenges

>> Where AI and automation are (and aren’t yet) transforming pharmaceutical formulation

Meet our guest

Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he’s especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis. 

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Wesley Tatum on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation.

What You'll Learn in This Episode:

>> How predictive modeling eliminates trial-and-error in drug formulation

>> The role of AI/ML in improving manufacturing efficiency and reducing downtime

>> How Thermo Fisher’s ASAP program accelerates stability testing

>> The future of digital transformation in pharma, including OpenAI partnerships

>> Where human expertise fits in a digitally enhanced development pipeline

Meet Our Guest

Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe. 

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Anil Kane on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems.

What you'll learn in this episode:

>> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability.

>> The role of lab automation in boosting productivity and reducing manual tasks.

>> How Connect Enterprise integrates lab systems across vendors into a seamless workflow. 

>> Key considerations for implementing LIMS in startup versus established biotech environments.

>> The ROI of digital lab solutions in supporting scalable, compliant biotech operations.

Meet Our Guests

John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with John Liberty  on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences.

What You'll Learn in This Episode:

>> Why AI workloads in biotech demand specialized infrastructure

>> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences

>> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI

>> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost

>> Strategies for deploying, optimizing, and managing large-scale AI models

Meet Our Guests

Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction.

Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Hugo Shi  on LinkedIn 
• Connect with IIya Burkov on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery.

​​What You'll Learn in This Episode

>> Why federated learning is a game-changer for pharma data sharing and AI-driven research

>> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge

>> The role of structural benchmarking in model development and validation

>> How Apheris enables privacy-preserving collaboration between major pharma players

>>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy

Meet Our Guest

Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Robin Roehm  on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure.

​​What You'll Learn in This Episode:

>> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making

>> Why structured outputs and semantic layers are key to high-quality AI-driven insights

>> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation

>> How feedback loops and model evaluations drive product reliability and user trust

>> The future of AI in biotech: continuous decision-making and multimodal intelligence

Meet Our Guests

Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions.

Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Alex Telford  on LinkedIn 
• Connect with Maged Ahmed on LinkedIn

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D.

​​What You'll Learn in This Episode:

>> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data

>> What federated learning means for IP protection and collaborative data sharing in biotech

>> Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability

>> How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution

>> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development

Meet Our Guest

Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Aliza Apple  on LinkedIn 

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.